601 Results for “COVID%2019”

That’s the amount of buybacks U.S. corporations funneled to shareholders during the past decade—rather than invest in technologies for the common good. This article is being published jointly by INET and The American Prospect

A review of regional integration in Africa

“But COVID vaccines are by no means unique — most medicines developed and approved in the United States involve taxpayer investment. Between 2010 and 2019, every single new medicine approved by the Food and Drug Administration included taxpayer-funded research through NIH. Drug companies patent the drugs we pay to develop and then charge us exorbitant prices for them that increase every year — sometimes twice a year.” — Terry Minow, Missoulian

Colleges and universities need to be saved, not only from financial ruin, but also, all too often, from themselves.

Gilead’s shareholders want exorbitant profits from Remdesivir, even though it was the public that enabled its development.

By all accounts infection rates have ebbed. But were we good or were we lucky?

The world is on edge at the prospect of a resurgent wave of infections. Models and speculation are rife, but facts remain scarce, which is why the events in Wisconsin on April 7, and their eventual impact, are so important.

Incomes Destroyed at the Bottom, Profits Supported at the Top

The speed and duration of COVID-19 economic recovery will depend on how the government will finance emergency programs.

An introduction to a series of interviews conducted by Dr. Dr. Folashadé Soulé and Dr. Camilla Toulmin in support of INET’s Commission on Global Economic Transformation (CGET)

The economy is likely to be crippled for months and fiscal rescue on a large scale, once again, is very much necessary.

Mortality and economic data show how constraints to government spending and a skepticism of redistributive policies have made the pandemic far worse

Evidence sharply contradicts PhRMA’s contention that its member companies need unregulated drug prices to generate profits that they then reinvest in drug innovation.

Bank failures don’t threaten most deposits, but they do threaten jobs